Qiagen RNeasy - Search Videos

Retsch Qiagen Tissuelyser II Sample Disruptor with Tube Adapter

Retsch Qiagen Tissuelyser II Sample Disruptor with Tube Adapter

YouTubeAlternative Lab Source

Qiagen N V QGEN Q3 2025 Earnings Call

Qiagen N V QGEN Q3 2025 Earnings Call

We exceeded our outlook for Q3 2025, raised our FY 2025 adjusted EPS target, announced the Parse acquisition and $500 million share repurchase to be completed in early January 2026. Learn more 👉 https://tinyurl.com/4292kbap ◾ Q3 2025 results: Net sales of $533 million ( 6% at actual rates); diluted EPS $0.60 ➡ Core sales 6% CER (constant exchange rates) driven by QIAstat-Dx ( 11% CER), QuantiFERON ( 11% CER) and Sample technologies ( 3% CER) ➡ Adj. operating income margin steady at 29.6% ➡ Adju

We exceeded our outlook for Q3 2025, raised our FY 2025 adjusted …

559 views1 week ago

Qiagen N.V. Just Beat EPS By 30%: Here's What Analysts Think Will Happen Next

Qiagen N.V. Just Beat EPS By 30%: Here's What Analysts Think Will H…

YahooSimply Wall St

See more videos